Table 1 Studies included in database
Study | Design | Setting | Subjects | Treatment | Key assessments at baseline (1st injection) visit |
|---|---|---|---|---|---|
ANCHOR-CD (NCT01314365) [16] | 1-year, non-interventional, registry study | 41 sites in the USA | 350 adult subjects with CD | AbobotulinumtoxinA (100%) | â–ª Demographics â–ª Medical history â–ª AbobotulinumtoxinA injection details â–ª TWSTRS â–ª CDIP-58 â–ª PNRS |
INTEREST IN CD1 (NCT00833196) [17] | Non-interventional study following a single BoNT-A injection cycle | 38 sites across Australia and Europe | 404 adult subjects with CD and a TWSTRS severity score > 15 | AbobotulinumtoxinA (69%) OnabotulinumtoxinA (28%) IncobotulinumtoxinA (3%) | ▪ Demographics ▪ Medical history ▪ BoNT-A injection details ▪ TWSTRS ▪ Tsui scale (tremor) ▪ CDIP-58 |
INTEREST IN CD2 (NCT01753349) [18] | 3-year, non-interventional study following multiple BoNT-A injection cycles | 113 sites across Australia, Europe, Latin America, North Africa, Middle East, Asia, and USA | 1050 adult subjects with CD | AbobotulinumtoxinA (69%) OnabotulinumtoxinA (24%) IncobotulinumtoxinA (6%) | â–ª Demographics â–ª Medical history â–ª BoNT-A injection details â–ª TWSTRS â–ª Tsui scale (tremor) â–ª Likert scale (patient satisfaction)* |